Viatris Announces Positive Top-line Results from Phase 3 Study of EFFEXOR® in Japanese Adults with Generalized Anxiety Disorder (GAD)

Viatris Announces Positive Top-line Results from Phase 3 Study of EFFEXOR® in Japanese Adults with Generalized Anxiety Disorder (GAD)

Treatment with once-daily EFFEXOR® met primary and all secondary efficacy endpoints in outpatient adults with GAD.
7 hours ago
from: Longview News-Journal

Continue reading...
Anxiety disorder, Generalized anxiety disorder, Venlafaxine
More about this
- Viatris announces Effexor study achieves primary objective
Viatris announced top-line results of its Phase 3 study in Japan evaluating the safety and efficacy of Effexor in adults with generalized...
from: TipRanks